Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TRACON Pharmaceuticals, Inc. (TCON)
NASDAQ:TCON
RESEARCH TOOLSreports
TRACON Pharmaceuticals (TCON) Stock Price & Analysis
674 Followers
TCON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.59 - $36.78
Previous Close$2.11
Volume53.58K
Average Volume (3M)233.10K
Market Cap
$4.77M
Enterprise Value-$3.76M
Total Cash (Recent Filing)$8.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.4
Beta1.35
Next Earnings
May 15, 2024EPS Estimate
-$1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.20
Shares Outstanding2,275,225
10 Day Avg. Volume441,412
30 Day Avg. Volume233,100
Standard Deviation0.40
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-4.81
Price to Sales (P/S)0.43
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.31
Enterprise Value/Gross Profit-0.31
Enterprise Value/Ebitda-0.39
Forecast
1Y Price Target
$37.50Price Target Upside1689.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
TRACON Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressEnvafolimab has received Orphan Drug Designation and Fast Track Designation from the FDA, enhancing its regulatory pathway and market potential.
Financial PerformanceTRACON reported 4Q23 EPS of $0.01, exceeding the estimate of ($0.03) and increasing the FY24 EPS estimate, indicating better-than-expected financial performance.
Licensing And PartnershipsTRACON expects to license their Product Development Platform to other companies, potentially extending their runway.
Bears Say
Clinical Trial ResultsThe independent data monitoring committee observed a lower overall response rate by blinded independent central review.
Financial ForecastFY24 and FY25 EPS estimates move to ($4.04) and ($5.66) from ($0.20) and ($0.27), respectively, after the reverse stock split.
Market CompetitionCurrent response rates for TRACON's envafolimab are lower compared to competitors like Keytruda and Opdivo + Yervoy.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TCON FAQ
What was TRACON Pharmaceuticals, Inc.’s price range in the past 12 months?
TRACON Pharmaceuticals, Inc. lowest stock price was $1.59 and its highest was $36.78 in the past 12 months.
What is TRACON Pharmaceuticals, Inc.’s market cap?
Currently, no data Available
When is TRACON Pharmaceuticals, Inc.’s upcoming earnings report date?
TRACON Pharmaceuticals, Inc.’s upcoming earnings report date is May 15, 2024 which is in 25 days.
How were TRACON Pharmaceuticals, Inc.’s earnings last quarter?
TRACON Pharmaceuticals, Inc. released its earnings results on Mar 05, 2024. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of -$1.6 by $1.8.
Is TRACON Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts TRACON Pharmaceuticals, Inc.’s price is currently Undervalued.
Does TRACON Pharmaceuticals, Inc. pay dividends?
TRACON Pharmaceuticals, Inc. does not currently pay dividends.
What is TRACON Pharmaceuticals, Inc.’s EPS estimate?
TRACON Pharmaceuticals, Inc.’s EPS estimate is -$1.19.
How many shares outstanding does TRACON Pharmaceuticals, Inc. have?
TRACON Pharmaceuticals, Inc. has 2,275,225 shares outstanding.
What happened to TRACON Pharmaceuticals, Inc.’s price movement after its last earnings report?
TRACON Pharmaceuticals, Inc. reported an EPS of $0.2 in its last earnings report, beating expectations of -$1.6. Following the earnings report the stock price went up 5.067%.
Which hedge fund is a major shareholder of TRACON Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TCON
---
TRACON Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.50 (1689.98% Upside)
$37.50 (1689.98% Upside)
Blogger Sentiment
Neutral
TCON Sentiment 50%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-93.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-48.10%
Trailing 12-Months
Company Description
TRACON Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
---
TCON Earnings Call
Q4 2024
0:00 / 0:00
---
TCON Stock 12 Months Forecast
Average Price Target
$37.50
▲(1689.98% Upside)
Technical Analysis
Best Analysts Covering TCON
1 Year
1 Year Success Rate
0/23 ratings generated profit
1 Year Average Return
-63.54%
reiterated a buy rating 10 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -63.54% per trade.
---